Paradigm Biocapital Advisors LP Janux Therapeutics, Inc. Put Options Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding JANX
# of Institutions
228Shares Held
54.6MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$329 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$113 Million0.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$97.2 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$74.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$67.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.32B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...